ANRO
Alto Neuroscience, Inc.
There isn't enough reported data to score ANRO yet.
ANRO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ANRO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ANRO PE Valuation
ANRO has no meaningful PE right now: it lost money over the past year.
ANRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect ANRO's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
ANRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.45 | -$0.20 |
| Q2 2026 | -$2.43 | -$0.08 |
| Q1 2026 | -$2.43 | -$0.13 |
| Q4 2025 | -$2.19 | +$0.31 |
| Q3 2025 | -$2.25 | +$0.15 |
| Q2 2025 | -$2.35 | -$0.23 |
| Q1 2025 | -$2.30 | -$0.46 |
| Q4 2024 | -$2.50 | -$1.15 |
ANRO lost $2.45 per share over the past year, about the same as its loss the year before.
ANRO Quarterly Revenue
ANRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.8M | -$10.8M |
| Q2 2026 | -$19.8M | -$6M |
| Q1 2026 | -$27.6M | -$11.1M |
| Q4 2025 | -$11.5M | +$2M |
| Q3 2025 | -$9.9M | +$2.8M |
| Q2 2025 | -$13.8M | -$1.7M |
| Q1 2025 | -$16.6M | -$5.4M |
| Q4 2024 | -$13.5M | -$1.7M |
ANRO has burned cash in almost every quarter: −$80M over the past year, against −$54M the year before.
ANRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.7% | +3.7M shares |
| 1 year | +72% | +19.4M shares |
| 3 years | +73% | +19.6M shares |
ANRO has 47M diluted shares, up 72% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
ANRO Net Leverage
ANRO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ANRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.8 | Neutral |
| Stochastic | 29.7 | Neutral |
ANRO's weekly RSI is 60 (neutral) and its Stochastic is 30 (neutral).
ANRO PE vs Healthcare Sector
ANRO has no meaningful PE right now: it lost money over the past year.
ANRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.7 | 24% above |
| 20 week MA | $27.9 | 9.6% above |
| 50 week MA | $23.2 | 32% above |
| 100 week MA | $13.9 | 121% above |
ANRO is in an uptrend: it's above all four of its weekly moving averages, and 121% above its 100-week average.
ANRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $20.7 | $4.31 | -79% |
| 2025 | $4.31 | $18.4 | +328% |
| 2026 YTD | $18.4 | $30.6 | +66% |
ANRO's yearly returns have swung widely, from +328% in 2025 to −79% in 2024. It's up 66% so far in 2026.